Studies&Me offers a digital platform for clinical study conduct to help pharma and biotech companies bring new treatment to patients faster.
Clinical drug development is a time-consuming and complex process that takes between 6-15 years. The cost of developing a new drug, from research and development to marketing approval, is extremely costly to pharma and biotech companies. Over two-thirds of the total cost, in both money and time of the discovery and development of a new drug is embedded in the clinical testing phases. Patient recruitment and retention issues are a costly challenge for companies conducting clinical studies - a lot of money can be saved if more patients are successfully recruited, enrolled and retained in clinical studies.
Studies&Me offers a digital platform for clinical study conduct to help pharma and biotech companies bring new treatment to patients faster. Studies&Me is a digital Contract Research Organization (CRO) offering support in the development of disease treatments. We strive to accelerate treatment development through decentralized clinical study designs for both interventional and observational studies. Decentralization of clinical trials by means of digitization accelerates treatment development, improves retention of patients, improves data load and quality by seamless real-time data capture and as a result, reduces the time and costs involved in bringing a new drug to market.
A decentralized, siteless study demonstrates high adherence, low dropout rate and completed four weeks before deadline, while enabling recruitment with broad geographic reach throughout the full spectrum of disease severity. A wide diversity of patients with skin diseases and diabetes can be recruited effectively through social media, both from a time and cost perspective. Smartphone photos, passive mobile obtained data points and questionnaires can be successfully used for remote assessment of disease severity such as eczema.
Business Model: B2B – pharma- and biotech companies.
Therapeutic Area: Dermatology, endocrinology, obesity.
Maturity Stage: Business is active, revenue generating.
'We can go much faster. However, I believe the most important factor is that it will be a far better journey for the patients participating in the trial. Finally, I also believe that the quality of the trial is better when patents are engaged and monitored more frequently as compared with a traditional trial.' - CEO, Pharma company